Christine E. Codding

Author

University of Oklahoma Health Sciences Center

Also Known As

Christine Codding, Christine E Codding, Christine E. Codding

Publications

1.9K

Citations

H-Index

Concepts

All Affiliations

University of Oklahoma Health Sciences Center Stanford University Desert Medical Imaging Palo Alto University Medical Plus

About

Christine E. Codding is an author at University of Oklahoma Health Sciences Center specializing in medicine, antibiotics, and clinical trials.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	423
2	Nephrology	1	1	33
3	Pathology	1	1	33
4	Rheumatology	1	1	390
5	Acute Kidney Injury	1	1	33

Christine E. Codding

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trial Clifton O. Bingham, R. John Looney, Atul Deodhar, Arthritis & Rheumatism	2009	458
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial Peter Nash, Bruce Kirkham, Masato Okada, The Lancet Rheumatoid DisorderRheumatologySpirit-p2 Phase 3Autoimmune DiseaseMedicine	2017	390
Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study Iain B. McInnes, Liz Thompson, Jon T. Giles, Annals of the Rheumatic Diseases	2013	314
Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study Mark C. Genovese, Patrick Durez, Hanno B. Richards, Annals of the Rheumatic Diseases	2012	286
Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double‐Blind, Active Comparator– and Placebo‐Controlled Study Francisco J. Blanco, R Möricke, Eva Dokoupilová, Arthritis & Rheumatology	2017	172
One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study Mark C. Genovese, Patrick Durez, Hanno B. Richards, The Journal of Rheumatology	2014	97
Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease‐Modifying Antirheumatic Drugs in the Treatment of Moderate‐to‐Severe Rheumatoid Arthritis Mark C. Genovese, Maria Greenwald, Christine E. Codding, Arthritis & Rheumatology	2017	89
Tubulointerstitial Nephritis Due to Vancomycin Christine E. Codding, Larry Ramseyer, Michael Allon, American Journal of Kidney Diseases GlomerulonephritisUrologyAntibioticsTubulointerstitial Nephritis DuePathology	1989	33
Economic evaluation of controlled-release oxycodone vs oxycodone-acetaminophen for osteoarthritis pain of the hip or knee. Deborah A. Marshall, Marcie Strauss, Dan Pericak, PubMed	2006	19
Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study Mark C. Genovese, Maria Greenwald, Sergio Gutiérrez‐Ureña, Rheumatology and Therapy	2019	15

Page 1